The University of Surrey’s Cancer Research Institute is collaborating on a new study to assess the feasibility of using blood tests to detect prostate cancer.
Surrey researchers are working with life sciences company VolitionRx Limited on the project, which will analyse blood samples to investigate the use of VolitionRx Limited’s NuQ® blood tests to both detect prostate cancer and highlight patients who require aggressive treatment.
If the test proves effective, it could result in better diagnosis and outcomes for patients with the disease.
The retrospective study will include the analysis of 550 blood samples from patients grouped into three categories: those with aggressive prostate cancer, those with indolent or slow-growing prostate cancer and age-matched healthy controls.
Professor Hardev Pandha, Director of the Surrey Cancer Research Institute and Professor of Urological Oncology, said: "There is an unmet medical need for better diagnostics in prostate cancer. It is our hope that VolitionRx's NuQ® tests will enable non-invasive and cost-effective blood testing that will result in better diagnosis and treatment, and improved outcomes, for patients with prostate cancer.”
VolitionRx Chief Scientific Officer, Dr Jake Micallef, said: "I am pleased that we have been able to commence this work in collaboration with Professor Hardev Pandha from the University of Surrey, who is very experienced and well-known in the field of prostate cancer diagnostics.
“Early detection and the ability to differentiate men with aggressive tumours requiring immediate treatment from men with slow-growing tumours that do not require aggressive treatment are important goals in the field of prostate cancer research.”
Read VolitionRx Limited's full press release about the research.
Prostate cancer facts
- Approximately 14 per cent of men will be diagnosed with prostate cancer at some point during their lifetime
- In the UK, about one in eight men will get prostate cancer at some point in their lives.
- More than 80 per cent of all prostate cancers are detected at the local stage. Nearly 100 per cent of men diagnosed and treated at this stage will be disease-free after five years, but a small percentage of men will experience more aggressive forms of prostate cancer